For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Plasma Urate and Progression of Mild Cognitive ImpairmentIrizarry M.C.a · Raman R.c, d · Schwarzschild M.A.a · Becerra L.M.c · Thomas R.G.c, d · Peterson R.C.e · Ascherio A.b · Aisen P.S.d
aDepartment of Neurology, Massachusetts General Hospital,and bDepartment of Epidemiology, Harvard School of Public Health, Boston, Mass., cDivision of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, and dDepartment of Neurosciences, University of California San Diego, San Diego, Calif., and eDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minn., USA Corresponding Author
Michael C. Irizarry, MD
WW Epidemiology, GlaxoSmithKline
5 Moore Drive, 17.2123
Research Triangle Park, NC 27709 (USA)
Tel. +1 919 483 7701, Fax +1 919 315 4947, E-Mail firstname.lastname@example.org
Background: Impaired antioxidant defenses are implicated in neurodegenerative disease. The plasma levels of urate, a water-soluble antioxidant, are reduced in Alzheimer’s disease (AD). Objective: We aimed to test the hypotheses that high plasma urate at baseline is associated with: (1) a reduced rate of conversion from mild cognitive impairment (MCI) to AD and (2) a lower rate of cognitive decline in MCI. Methods: Plasma urate was obtained at baseline from 747 participants in a 3-year, randomized, double-blind, placebo-controlled study of donepezil, vitamin E or placebo for delaying the progression of MCI to AD.The association between baseline urate and conversion from MCI to AD was examined by Cox proportional hazards regression. The relationship between baseline urate and cognitive change on the cognitive subscale of the Alzheimer’s Disease Assessment Scale was evaluated by longitudinal analysis. Results: Baseline plasma urate was not associated with the rate of conversion of MCI to AD. In the placebo arm, high plasma urate was related to a slower rate of cognitive decline over 3 years, although this was not reproduced in the other treatment arms. Conclusion: While plasma urate levels did not predict the progression of MCI to AD, high urate may be associated with a reduced rate of cognitive decline in MCI patients not treated with donepezil or vitamin E. The results support the investigation of biomarkers of antioxidant status as risk factors for cognitive decline in MCI.
© 2008 S. Karger AG, Basel